Amedisys (AMED) Tops Q2 EPS by 18c
Tweet
Share
E-mail
Get Alerts AMED Hot Sheet
Join SI Premium – FREE
Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.54, $0.18 better than the analyst estimate of $1.36. Revenue for the quarter came in at $621.86 million versus the consensus estimate of $612.57 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades Yangzijiang Shipbuilding (YZJSGD:SP) (YSHLF) to Overweight
- Jefferies Starts Zhejiang Jiuli Hi-Tech Metals (002318:CH) at Buy
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
